PhRMA Sues FTC To Halt Rule On Drug Patent Licensing Deals
Executive Summary
PhRMA says the reporting rule is discriminatory since it singles out one industry; the association brought four suits against government agencies in 2013.
You may also be interested in...
PhRMA Seeking Injunction Against 340B Orphan Drug Exclusion Rule
The trade group files a lawsuit seeking preliminary and permanent injunctions against implementation of a final rule that requires 340B discounts for the non-orphan uses of drugs with an orphan designation.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.